What Pentoxifylline SR Sanofi Treats: Main Uses and Benefits

Pentoxifylline SR (Sustained Release) is generally used to address symptoms related to physical discomfort across conditions where functional stability becomes affected. This therapeutic approach is commonly used to help with circulation problems, most often associated with chronic occlusive arterial disease of the limbs, such as peripheral arterial disease (PAD). The medication is applied in addressing conditions presenting with systemic or localized discomfort, including intermittent claudication and related manifestations.

---

The medicine supports patients during episodes of heightened discomfort by providing supportive relief when symptoms interfere with routine activities. This medication contributes to easing the overall symptom load, including aching, cramping, and tiredness in the hands and feet. The medicine plays a role in managing symptoms that create noticeable physiological strain, helping patients cope more steadily with symptom fluctuations.

---

Quick Fact: Helps Manage Symptoms of Physical Discomfort

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility Profile: Pentoxifylline SR

This eligibility profile is based strictly on information documented in authoritative governmental regulatory sources, such as official prescribing information and summaries of product characteristics.

Populations Who Must NOT Use This Medicine (Contraindications)

Individuals are excluded from using this medicine if they have:

• Hypersensitivity or Allergy to pentoxifylline or to any other xanthine derivative (such as caffeine or theophylline).
• A history of recent cerebral hemorrhage or extensive retinal hemorrhage.
• A history of acute myocardial infarction or severe cardiac arrhythmias.
• Current or recent peptic ulceration (ulcers of the stomach or small intestine).

Populations Requiring Restricted or Conditional Use

Group	Restriction/Condition (Based on Official Labeling)
Pediatric Patients (<18 years)	Not recommended; safety and efficacy have not been established.
Severe Renal/Hepatic Impairment	Not recommended or requires significant dose reduction (e.g., if creatinine clearance is below 30 mL/min).
Pregnancy/Lactation	Use only if potential benefit outweighs risk; drug is excreted in human milk.
Geriatric Patients	Dose selection should be cautious, reflecting potential decrease in organ function.

Use is generally confined to adults (18 years and older) who do not have any of the stated contraindications.

The official regulatory documents specify several interaction patterns for this medicine. Co-administration with Ketorolac is formally prohibited due to a documented and significant increase in the risk of bleeding and/or prolonged prothrombin time, representing a contraindication based on interaction severity.

Pharmacokinetic Interactions (Exposure Modification)

Pentoxifylline modifies the systemic exposure of certain co-administered drugs. Concomitant use with Theophylline-containing drugs may lead to increased Theophylline plasma levels and associated toxicity risk. Additionally, co-administration with the H2-antagonist Cimetidine is reported to increase the steady-state plasma concentration of pentoxifylline and its active metabolites. Similarly, the use of strong CYP1A2 inhibitors (such as Ciprofloxacin or Fluvoxamine) may increase the overall systemic exposure to pentoxifylline.

Pharmacodynamic Interactions (Additive Effects)

Use with Anticoagulants (Vitamin K Antagonists) or Platelet Aggregation Inhibitors (e.g., Aspirin, Clopidogrel) increases the documented risk of bleeding. Furthermore, the physiological action of Antihypertensive agents and Antidiabetic agents (including insulin and oral agents) may be potentiated, leading to documented additive effects on blood pressure or blood sugar.

Population and Administration Notes

In patients with hepatic or renal impairment, exposure to pentoxifylline and its active metabolites is officially reported to be increased. Co-administration with meals results in a minor pharmacokinetic interaction described as a small increase in drug exposure (AUC and Cmax).

How Pentoxifylline SR Sanofi Works

Pentoxifylline SR operates through a multifaceted mechanism primarily focused on modifying the physical properties of blood and modulating chronic vascular inflammation.

---

Molecular Modulation of Blood Cell Flexibility

This mechanism begins with the inhibition of Phosphodiesterase (PDE) enzymes within circulating blood cells, which raises the level of the intracellular messenger cyclic AMP (cAMP). This cAMP-driven cascade activates Protein Kinase A, which then phosphorylates proteins in the red blood cell membrane. The resulting physiological effect is an increase in red blood cell deformability and flexibility, promoting their passage through narrow microvessels.

---

️ Hemorheology and Microcirculatory Modulation

The resulting flexibility of red blood cells, combined with the drug’s action to reduce plasma fibrinogen levels and decrease platelet aggregation, leads to a core effect known as hemorheological modification. This mechanism results in a reduction in the overall viscosity of the whole blood, thereby modulating the flow characteristics and contributing to blood passage through the microcirculation.

---

️ Downregulation of Vascular Inflammation

Beyond its effect on blood flow, the drug engages mechanisms to modulate the vascular inflammatory response. By suppressing transcription factors like NF-kappaB and reducing the release of pro-inflammatory cytokines (e.g., TNF-alpha) from immune cells, the mechanism helps to limit leukocyte adhesion to the endothelium. This supplementary action modulates inflammation and cellular stickiness, which complements the primary hemorheological action.

How to Use Pentoxifylline SR Sanofi

Pentoxifylline SR is strictly for oral administration and is supplied as a 400 mg prolonged-release tablet, a formulation designed to release the active substance over an extended period. Proper usage focuses on maintaining a consistent daily schedule and correct handling of the sustained-release form.

---

Standard Administration Principles

Entity	Official Administration Guideline
Route of Administration	By mouth (oral) only.
Standard Dosing Schedule	Usually 400 mg three times a day (TID). Dosing may be reduced to 400 mg twice a day (BID) if necessary due to intolerance.
Timing with Meals	Tablets must be taken with or immediately after meals to minimize potential gastrointestinal upset.
Tablet Handling	The prolonged-release tablet must be swallowed whole and should not be crushed, broken, or chewed.

---

Use Patterns and Adjustments

Treatment with Pentoxifylline SR is typically a long-term strategy for managing chronic conditions. It is standard practice that therapy should be continued for at least eight weeks before a final assessment of efficacy is made.

In specific populations, the standard regimen may require adjustments:

• Renal Impairment: For patients with reduced kidney function (creatinine clearance below 30 mL/min), a dose reduction of approximately 30% to 50% is required, often resulting in a 400 mg once or twice daily regimen.
• Hepatic Impairment: Dose reduction is also necessary for patients with severely impaired liver function, with the final dosage guided by patient tolerance.

If a dose is missed, it should be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose must be skipped entirely, and the regular schedule resumed. Double doses should not be taken to make up for a missed dose.

Research Evidence Overview of Pentoxifylline SR Sanofi

This overview describes the official research and scientific reviews that form the evidence base used by health authorities to evaluate pentoxifylline. The information below focuses only on the scope and findings of controlled trials, staying neutral and non-advisory.

Evidence for Use in Intermittent Claudication

The research exploring pentoxifylline primarily focuses on its use for intermittent claudication, which is the cramping or pain in the legs that occurs during exercise and is linked to chronic occlusive arterial disease. The evidence base includes many Randomized Controlled Trials (RCTs) and subsequent systematic reviews that combine and analyze the findings from these individual studies.

Research monitored the data patterns observed in groups receiving pentoxifylline compared to groups receiving an inactive placebo. Studies monitored changes in functional capacity, which were primarily measured by standardized treadmill tests. The synthesis of findings is part of the broader evidence landscape; however, due to variability across the different trials, the certainty of the evidence remains classified as low to moderate.

Study Outcomes: How Functional Capacity Was Measured

Studies primarily explored outcomes related to physical discomfort and daily functioning or activity level. The researchers measured objective metrics such as pain-free walking distance (PFWD) and total walking distance (TWD) to quantify how far patients could walk before pain started or before they had to stop entirely. Trials also monitored patient-reported outcomes describing perceived discomfort. Findings described patterns observed in the studies related to these walking and symptom changes; research so far indicates that results were mixed, and the measured change in walking ability was observed to be small.

Duration of Follow-up and Long-Term Data

The majority of the controlled clinical research that forms the core evidence base for pentoxifylline consists of studies with relatively limited follow-up durations. Many of the RCTs that have been combined in meta-analyses lasted six months or less. Patterns related to short-term changes have been documented, but the durability of these observations over many years is not fully established. There is limited information from extended studies that track outcomes beyond the intermediate term, leaving the long-term effects on functional capacity or disease progression not well characterized.

Research Gaps and Areas of Uncertainty

Evidence quality varies across studies; many older trials included in the analyses have methodological variability or an unclear risk of bias, which influences the certainty of the findings. Evidence for comparison against other approaches for managing chronic arterial disease is limited. Furthermore, the relationship between the drug's intended action and long-term, patient-relevant outcomes like avoiding amputation or improving overall survival is not fully established, meaning research is ongoing.

Key Studies & References

1. Pentoxifylline NIH MedlinePlus Drug Information (Regulatory/Label Context)
2. Peripheral arterial disease: diagnosis and management (NICE Guideline CG147)
3. Pentoxifylline use in diabetic nephropathy: systematic review and meta-analysis of randomized controlled trials (BMC Nephrology)

Common questions about Pentoxifylline SR Sanofi (FAQ)

---

Q: How long does it typically take for Pentoxifylline SR to start working?

Official prescribing information indicates that a patient may begin to notice clinical effects, such as improvement in related symptoms, within two to four weeks of starting therapy. However, the maximum benefit of the medication is typically observed only after eight weeks of continuous treatment. A final assessment of the drug’s observed effect is typically documented after this period in clinical research.

---

Q: Is Pentoxifylline SR a blood thinner?

Pentoxifylline is officially classified as a hemorheologic agent, meaning it works by improving the flow properties of the blood, rather than being a traditional blood thinner. However, because the medication can reduce the ability of blood platelets to clump together, regulatory documents note that combining it with other blood thinners (like antiplatelets or anticoagulants) can increase the risk of bleeding.

---

Q: Are there any common interactions with over-the-counter pain relievers like Ibuprofen?

Official regulatory warnings state that using Pentoxifylline SR with antiplatelet drugs and certain nonsteroidal anti-inflammatory drugs (NSAIDs), which include common pain relievers like Ibuprofen or Aspirin, can increase the risk of bleeding. Regulatory warnings state that a healthcare provider should be aware of all over-the-counter medicines being used.

---

Q: Does Pentoxifylline SR interact with any common vitamins or herbal supplements?

Official product information states that a healthcare provider should be aware of all supplements, vitamins, and herbal products being taken, as some may interact with the medicine. For example, some common supplements, such as ginkgo or garlic, may carry a potential to increase the risk of bleeding when used alongside this medication.

---

Q: Is it okay to drink coffee while taking this medication?

Pentoxifylline is structurally similar to other methylxanthine compounds, which include caffeine (found in coffee) and theophylline. Official contraindications state that this drug should not be used by patients who have previously exhibited intolerance or allergy to methylxanthine derivatives.

---

Q: Does Pentoxifylline SR work for nerve pain or just circulation?

The only official indication listed in regulatory documents for this drug is the treatment of intermittent claudication, which is pain in the legs caused by chronic occlusive arterial disease (a circulation problem). There is no official regulatory indication or approval for the use of this drug specifically to treat nerve pain.

---

Q: Does Pentoxifylline SR affect blood pressure?

Regulatory documents report that Pentoxifylline SR may increase the effectiveness of blood pressure-lowering medications, potentially leading to an additive effect on blood pressure. Furthermore, hypotension (low blood pressure) has been reported in clinical trials as a less common adverse reaction.

---

Q: Can this medication affect the results of blood tests?

Official warnings indicate that if this medication is used alongside blood thinning agents, close monitoring of anti-coagulant activity via blood tests is required. Additionally, in rare cases, adverse reactions have included a decrease in specific blood cell counts or an increase in liver function test results.

---

Q: Is Pentoxifylline SR Sanofi safe to take if I have diabetes?

Official product information states that Pentoxifylline SR may potentiate, or strengthen, the effect of antidiabetic medications, including insulin, leading to additive effects on blood sugar levels. According to regulatory information, patients with diabetes often require close and consistent monitoring of their blood sugar when beginning or adjusting the dose of this medicine.

---

Q: Does Pentoxifylline SR cause weight changes?

According to product monographs, weight change is listed as a less common adverse drug reaction reported in clinical trials. It is described as occurring in less than 1% of patients studied.

---

Q: How quickly does Pentoxifylline SR leave the system?

The active substance (pentoxifylline) is known to be metabolized very rapidly by the body, with a short elimination half-life of less than one hour. However, the drug is quickly converted into active metabolites, which are responsible for its therapeutic effect and remain in the body for a slightly longer duration.

---

Q: Are there reports of sleep disturbances from taking Pentoxifylline SR?

Yes, regulatory documents list potential central nervous system side effects. These have included reports of both insomnia (difficulty sleeping) and other sleep disturbances such as drowsiness or sleepiness, which were reported as less common adverse reactions.

---

Q: Is Pentoxifylline SR considered a high-risk medication?

Official documents highlight the potential for serious adverse events, including the critical risk of hemorrhage, especially in the brain or retina, or when used with other blood thinners. The drug is also contraindicated for patients with recent bleeding events or severe allergic reactions like anaphylaxis.

---

Q: Does this medicine have a known effect on liver function?

Yes, official adverse reaction reports list several effects on the liver. Less common reactions have included hepatitis (liver inflammation), jaundice, intrahepatic cholestasis, and increased levels of liver enzymes (transaminase elevation).

---

Q: Is it true that Pentoxifylline SR can help with wound healing?

The official regulatory indication for this drug is the treatment of symptoms related to peripheral vascular disorders, specifically intermittent claudication or trophic ulcers. Trophic ulcers are wounds related to poor blood circulation, suggesting that the medicine's mechanism may benefit this related area.

---

Q: Does Pentoxifylline SR interact with common anti-depressants?

Official interaction warnings specify that certain medications, including some anti-depressants like Fluvoxamine, can affect the way the body breaks down Pentoxifylline SR. This type of interaction may lead to an increased level of Pentoxifylline in the body, potentially raising the risk of side effects.

Storage and Disposal Requirements

Pentoxifylline extended-release tablets must be stored according to regulatory labeling to maintain product stability and safety. The required storage environment is Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The medicine must be kept in its original container with the cap tightly closed and protected from excess heat, moisture, and freezing. A mandatory requirement is to store the tablets out of the sight and reach of children.

Disposal should prioritize official drug take-back programs or mail-back envelopes for unused or expired product. The medication must not be disposed of by flushing or pouring into any wastewater system. If household trash disposal is necessary, the tablets must be mixed with an unappealing substance, but not crushed, before being sealed and discarded.